Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態
スポンサー
Baylor College of Medicine

キーワード

概要

The primary objective of this study is to evaluate the efficacy of administering intravenous dexmedetomidine as a single preemptive dose to placebo in reducing the total 24 hour dose of opioids as measured on a weight adjusted morphine equivalent basis.

説明

The eligibility of the patient to participate in this study will be determined by the Investigator on the basis of the inclusion and exclusion criteria. Consent will be obtained from eligible patients only.

The following is the standard intraoperative anesthesia protocol utilized at Texas Children's Hospital for all children undergoing this procedure of cleft palate repair even if they are not part of the study: (1) Induction of anesthesia via a face mask with sevoflurane 6-8% and 70% N2O / 30% O2 (2) A peripheral IV will be inserted and glycopyrrolate 5-10 mcg/kg IV administered to dry oral secretions and reduce vagal responses. (3) Tracheal intubation using appropriate equipment in keeping with the clinical judgment of the anesthesia care provider. The protocol will permit the administration of propofol up to 3 mg/kg over 20-30 seconds to increase the depth of anesthesia prior to tracheal intubation if the Attending Anesthesiologist deems it necessary. (4) General anesthesia maintained with Sevoflurane/isoflurane with inhaled concentrations adjusted to keep blood pressure and heart rates within 20% of baseline. (5) Nitrous oxide will be discontinued and the lowest inspired oxygen concentration will be administered to reduce risks of airway fires while avoiding hypoxemia. (6) Fentanyl 1-2 mcg/kg administered at the start of the procedure with subsequent fentanyl 1 mcg/kg boluses as needed if the heart rate and blood pressure are increased per vital signs (HR and BP) variance greater than 20% of baseline (7) Dexamethasone 0.5 mg/kg IV. (8) Rocuronium 0.6 -1 mg/kg IV may be administered for paralysis if this is clinically indicated in the opinion of the Attending Anesthesiologist. (9) Local infiltration with 0.5% lidocaine with 1:200,000 epinephrine will be administered by the surgeon at the site of the palatoplasty in keeping with our current surgeon practice. (10) Ondansetron 0.1 mg/kg IV at the end of the procedure (11) Anesthetic gases will be discontinued at the end of the procedure and 100% oxygen administered prior to tracheal extubation. If rocuronium was used neuromuscular blockade will be antagonized with neostigmine 0.07 mg/kg and glycopyrrolate 10 mcg/kg. The timing of tracheal extubation will be based on clinical indications and the judgment of the Attending Anesthesiologist.

The above standardized management will be followed for all children undergoing this operation even if they are not part of the study. The experimental part of the protocol will involve randomization of subjects in a 1:1 ratio to receive intravenous dexmedetomidine or placebo. Randomization will occur by the pharmacy using a computer generated random number. The study will be double-blind with respect to the treatment assignment. The investigational pharmacy will mix and deliver either dexmedetomidine 1 mcg/kg in a concentration of 4 mcg/ml or placebo to the anesthesia provider on the day of surgery. The assigned study drug will be administered when the heart rate and blood pressure have returned to acceptable stable levels after tracheal intubation and before the surgeon has started the palatal injection of lidocaine with epinephrine. Placebo or dexmedetomidine will be administered in a similar fashion as an IV infusion over 10 minutes as recommended to avoid bradycardia,hypertension, hypotension or other cardiac events. . Persistent bradycardia (greater than 30% reduction from baseline for more than 1 minute) will be managed with administration of atropine 0.01 mg/kg. An immediate rise in blood pressure will be treated with an increase in the inspired concentration of inhaled anesthetics. If there is hypertension (greater than 30% rise in value from baseline), the inspired concentration of inhaled anesthetics will be increased. Persistent hypotension (greater than 30% decrease from baseline levels for more than 1 minute) will be treated with fluid bolus of 5-10 ml/kg and decreasing the concentration of the volatile anesthetic. Other drugs may be used in keeping with the clinical judgment of the Attending Anesthesiologist.

Postoperative management will not be changed for the purposes of the study. In keeping with standard practices in the TCH, all patients in the PACU will be monitored with continuous pulse oximetry, EKG and serial non-invasive blood pressure measurements. Pain will be assessed using an age appropriate observational scale- the FLACC score for younger patients and the FACES score for older co-operative patients. Pain scores are recorded on arrival to the PACU, when awake and at 30 minute intervals. If the FLACC score is greater than 4 or the FACES greater than 2, patients will receive morphine 25 mcg/kg IV to be repeated as required in 10 minutes if adequate pain control has not been achieved. Supplemental oxygen will be administered till the child can maintain an oxygen saturation greater than 92% in room air. Emergence delirium will be determined using the PAED score and children with scores of greater than 12 will receive therapy in keeping with the clinical judgment of the Attending Anesthesiologist (additional opioids or IV propofol). The child will be discharged to the floor when awake, can maintain patency of the airway, have stable vital signs, a pain score less than 4 and an Aldrete score of at least 9.

Patients will be transferred to the floor where they will receive the current standard postoperative regimen used by our plastic surgery service care for this procedure. This will includeHycet 0.135mg/kg every 4 hours when needed. Morphine 0.025 mg/kg IV every 4 hours will be made available as a rescue analgesia for break through pain. Nurses record pain scores on the FLACC or FACES scale depending on the age of the patient and ability to cooperate. Rescue analgesia will be provided based on a nursing assessment that the pain is poorly controlled (FLACC score greater than 4 or FACES score greater than 2) after receiving oral pain medications. Non -steroidal anti-inflammatory drugs are usually avoided in these children because of concerns for bleeding from the raw mucosal surfaces at the site of the surgery.

We will record all perioperative, intraoperative and postoperative drugs administered to patients, pain scores, Pediatric Anesthesia Emergence Delirium (PAED) scores in the PACU, pain scores and rescue medications administered during the stay in the PACU and on the floor. The time to first rescue medication, oral intake, and discharge from the PACU and the hospital will also be recorded along with adverse events such as vomiting, constipation, pruritis, agitation, respiratory depression or excessive sedation. Any interventions to treat these will be noted.

日付

最終確認済み: 01/31/2019
最初に提出された: 09/22/2016
提出された推定登録数: 09/22/2016
最初の投稿: 09/25/2016
最終更新が送信されました: 02/03/2019
最終更新日: 02/04/2019
実際の研究開始日: 12/30/2017
一次完了予定日: 11/30/2019
研究完了予定日: 11/30/2019

状態または病気

Cleft Palate

介入/治療

Drug: Experimental group

Drug: Placebo group

段階

段階 4

アームグループ

介入/治療
Experimental: Experimental group
Intervention group 1: pre-operative administration of IV dexmedetomidine 1mcg/kg
Drug: Experimental group
Analgesic Efficacy
Placebo Comparator: Placebo group
Intervention group 2: placebo
Drug: Placebo group
Saline placebo

適格基準

研究の対象となる年齢 6 Months に 6 Months
研究に適格な性別All
健康なボランティアを受け入れるはい
基準

Inclusion Criteria:

- Patients between 6mo to 8 years of age scheduled to undergo primary or secondary cleft repair.

Exclusion Criteria:

- Patients with significant cognitive impairment

- Patients with various syndromes known to be associated with difficult airways(e.g. Goldenhar's syndrome, Treacher- Collins, Trisomy 13 or 18, Pierre Robin, etc.)

- Have a prior history of allergy, hypersensitivity or contraindication to any drug used for anesthesia including opioids (morphine, fentanyl, hydrocodone) and inhalation agents(i.e. children with susceptibility to malignant hyperthermia)

- Have a history of congenital bleeding diathesis(e.g. hemophilia) or any active clinically significant bleeding, impaired renal or hepatic function

- Children with heart failure, heart block, ventricular dysfunction, cardiomyopathy, myocarditis or congenital heart disease where cardiac output is rate dependent and relies on A-V synchrony (e.g. single ventricle). Children with well controlled atrial or ventricular septal defects, patent ductus arteriosus, repaired coarctation of the aorta will qualify if they have no cardiac rhythm or hypertension problems.

- Children with uncontrolled hypertension, intracranial vascular malformations, Moya Moya disease or intracranial hypertension.

- Any child who has received an investigational drugs within 30 days before study drug administration.

- Inability of the parent or legal guardian to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board) and agree to abide by the study restrictions.

- Be otherwise unsuitable for the study, in the opinion of the Investigator.

結果

主な結果の測定

1. Postoperative pain control [24 hours]

Assessment of and clinical measurement that one treatment group will be better with postoperative pain management than the non-treatment group, which would be similar to published data for children undergoing this procedure. This will be measured in a mean pain score. There will be integrating of pain scores and morphine consumption.

2. Opioid consumption [24 hours]

Opioid consumption is measured in mean morphine equivalent dose in mcg/kg, this will be integrated with the pain scores.

二次的な結果の測定

1. The number of children with FLACC scores greater than 4 [24 hours]

FLACC Pain Scores

2. Time to first rescue analgesia [24 hours]

Time in minutes to administration of first dose of rescue analgesia

3. Respiratory depression [24 hours]

Patients with SPO2 less than 85%

4. Postoperative vomiting [24 hours]

postoperative emesis

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge